I agree that this site is using cookies. You can find further informations here.
X
Zinzani P. L
483  results:
Search for persons X
?
1

Exposure to obinutuzumab does not affect outcomes of SARS‐C..:

Pinto, A. ; Caltagirone, M. ; Battista, M....
British Journal of Haematology.  , 2024
Link: https://doi.org/10.1111/..
 
?
2

MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI‐CD20 VE..:

Sehn, L. ; Sarkozy, C. ; Song, Y....
Hematological Oncology.  41 (2023)  S2 - p. 168-170 , 2023
Link: https://doi.org/10.1002/..
 
?
3

FAVEZELIMAB PLUS PEMBROLIZUMAB IN ANTI–PD‐1–REFRACTORY CLAS..:

Armand, P. ; Zinzani, P. L. ; Timmerman, J....
Hematological Oncology.  41 (2023)  S2 - p. 163-165 , 2023
Link: https://doi.org/10.1002/..
 
?
4

Final safety and efficacy results of copanlisib monotherapy..:

Dreyling, M. ; Santoro, A. ; Mollica, L....
Hematological Oncology.  41 (2023)  S2 - p. 560-562 , 2023
Link: https://doi.org/10.1002/..
 
?
5

An open‐label phase 1/2 study of favezelimab plus pembroliz..:

Lavie, D. ; Johnson, N. ; Borchmann, P....
Hematological Oncology.  41 (2023)  S2 - p. 364-366 , 2023
Link: https://doi.org/10.1002/..
 
?
6

PHASE 1B OPEN‐LABEL STUDY OF LONCASTUXIMAB TESIRINE IN COMB..:

Hess, B. T. ; Solh, M. M. ; Gandhi, M....
Hematological Oncology.  41 (2023)  S2 - p. 824-825 , 2023
Link: https://doi.org/10.1002/..
 
?
7

A phase 2 study of zilovertamab vedotin as monotherapy or i..:

Zinzani, P. L. ; Mayer, J. ; Benjamini, O....
Hematological Oncology.  41 (2023)  S2 - p. 564-565 , 2023
Link: https://doi.org/10.1002/..
 
?
8

AFM13 IN PATIENTS WITH CD30 POSITIVE RELAPSED OR REFRACTORY..:

Kim, W. S. ; Shortt, J. ; Zinzani, P. L....
Hematological Oncology.  41 (2023)  S2 - p. 195-196 , 2023
Link: https://doi.org/10.1002/..
 
?
9

EFFICACY AND SAFETY OF MOLTO, A MULTICENTER, OPEN LABEL, PH..:

Frustaci, A. M. ; Montillo, M. ; Rossi, D....
Hematological Oncology.  41 (2023)  S2 - p. 62-63 , 2023
Link: https://doi.org/10.1002/..
 
?
10

GLOFITAMAB PLUS POLATUZUMAB VEDOTIN DEMONSTRATES DURABLE RE..:

Hutchings, M. ; Avigdor, A. ; Sureda, A....
Hematological Oncology.  41 (2023)  S2 - p. 138-140 , 2023
Link: https://doi.org/10.1002/..
 
?
11

CART‐SIE REAL LIFE STUDY: PRIMARY MEDIASTINAL B‐CELL LYMPHO..:

Chiappella, A. ; Dodero, A. ; Guidetti, A....
Hematological Oncology.  41 (2023)  S2 - p. 198-199 , 2023
Link: https://doi.org/10.1002/..
 
?
12

PILOT PHASE II STUDY OF SELINEXOR IN COMBINATION WITH IFOSF..:

Chiappella, A. ; Dodero, A. ; Carniti, C....
Hematological Oncology.  41 (2023)  S2 - p. 845-846 , 2023
Link: https://doi.org/10.1002/..
 
?
13

BEGEV as salvage regimen in first setting for relapsed/refr..:

Carella, M. ; Argnani, L. ; Coppola, P. E....
Hematological Oncology.  41 (2023)  S2 - p. 360-361 , 2023
Link: https://doi.org/10.1002/..
 
?
14

Role of autologous stem cell transplantation or salvage che..:

Pellegrini, C. ; Casadei, B. ; Sutto, E....
Hematological Oncology.  41 (2023)  S2 - p. 368-369 , 2023
Link: https://doi.org/10.1002/..
 
?
15

The treatment of Burkitt lymphoma with the Berlin‐Frankfurt..:

Broccoli, A. ; Argnani, L. ; Gugliotta, G....
Hematological Oncology.  41 (2023)  S2 - p. 427-427 , 2023
Link: https://doi.org/10.1002/..
 
1-15